Yabao Pharmaceutical Group (600351.SH) plans to sell 62% equity of Taiyuan Pharmaceutical to TONYSHARE for 87.19 million yuan.

Yabao Pharmaceutical Group (600351.SH) announced that the company plans to sell 62% of the equity of its holding subsidiary Yabao Pharmaceutical Group Taiyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Taiyuan Pharmaceutical" or "the target company") to Shanxi TONYSHARE Technology Co., Ltd. (hereinafter referred to as "TONYSHARE") for a transaction price of 87.19 million yuan. After the completion of this transaction, TONYSHARE will hold 95% of Taiyuan Pharmaceutical's equity, and the company will hold 5% of Taiyuan Pharmaceutical's equity. Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements. This transaction is based on the company's future development considerations. It is beneficial for improving the company's asset operating efficiency, reducing management costs, enhancing the company's sustainable operational capabilities, and providing financial support for the company's business expansion. According to the company's preliminary estimates, it is expected that after the completion of this transaction, the company's profit for the year 2025 will increase by approximately 59 million yuan (unaudited).